Global Biosimilar Insulin Market Growth 2025-2031

Publication ID:

LPI05251765

Publication Date:

May 5, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Biosimilar Insulin market size is predicted to grow from US$ 3673 million in 2025 to US$ 8378 million in 2031; it is expected to grow at a CAGR of 14.7% from 2025 to 2031.
Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
The biosimilar insulin market is primarily driven by the growing demand for affordable diabetes management solutions. As the prevalence of diabetes continues to rise globally, especially in emerging markets, there is an increasing need for cost-effective alternatives to branded insulin products. Biosimilar insulins offer similar therapeutic effects as their originator counterparts but at a lower price, making them more accessible to patients and healthcare systems. Additionally, the expiration of patents for several major insulin products has opened the door for the introduction of biosimilars, further driving market growth. The increasing adoption of biosimilars in both developed and developing countries is expected to continue, as they help reduce the financial burden on healthcare systems while maintaining high standards of care.
However, the biosimilar insulin market faces challenges related to regulatory approval processes and market acceptance. Biosimilars, although similar in composition, are not identical to their reference biologics, leading to concerns over safety and efficacy, particularly in long-term use. Regulatory bodies require rigorous testing and clinical trials to ensure that biosimilar insulins meet the necessary standards, which can delay their entry into the market. Furthermore, the market is also challenged by resistance from healthcare professionals and patients who may be hesitant to switch from branded to biosimilar insulin due to unfamiliarity or perceived risks. Additionally, competition from other diabetes therapies, such as oral medications and innovative insulin delivery devices, could also impact the growth of the biosimilar insulin market.
Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%.
The 鈥淏iosimilar Insulin Industry Forecast鈥� looks at past sales and reviews total world Biosimilar Insulin sales in 2024, providing a comprehensive analysis by region and market sector of projected Biosimilar Insulin sales for 2025 through 2031. With Biosimilar Insulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar Insulin industry.
This Insight Report provides a comprehensive analysis of the global Biosimilar Insulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar Insulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Biosimilar Insulin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar Insulin and breaks down the forecast by Type, by Distribution Channel, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar Insulin.
This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Insulin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Segmentation by Distribution Channel:
Hospital
Retail Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Key Questions Addressed in this Report
What is the 10-year outlook for the global Biosimilar Insulin market?
What factors are driving Biosimilar Insulin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biosimilar Insulin market opportunities vary by end market size?
How does Biosimilar Insulin break out by Type, by Distribution Channel?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Biosimilar Insulin Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Biosimilar Insulin by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Biosimilar Insulin by Country/Region, 2020, 2024 & 2031
2.2 Biosimilar Insulin Segment by Type
2.2.1 Biosimilar Insulin Glargine
2.2.2 Biosimilar Insulin Lispro
2.2.3 Other
2.3 Biosimilar Insulin Sales by Type
2.3.1 Global Biosimilar Insulin Sales Market Share by Type (2020-2025)
2.3.2 Global Biosimilar Insulin Revenue and Market Share by Type (2020-2025)
2.3.3 Global Biosimilar Insulin Sale Price by Type (2020-2025)
2.4 Biosimilar Insulin Segment by Distribution Channel
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Others
2.5 Biosimilar Insulin Sales by Distribution Channel
2.5.1 Global Biosimilar Insulin Sale Market Share by Distribution Channel (2020-2025)
2.5.2 Global Biosimilar Insulin Revenue and Market Share by Distribution Channel (2020-2025)
2.5.3 Global Biosimilar Insulin Sale Price by Distribution Channel (2020-2025)
3 Global by Company
3.1 Global Biosimilar Insulin Breakdown Data by Company
3.1.1 Global Biosimilar Insulin Annual Sales by Company (2020-2025)
3.1.2 Global Biosimilar Insulin Sales Market Share by Company (2020-2025)
3.2 Global Biosimilar Insulin Annual Revenue by Company (2020-2025)
3.2.1 Global Biosimilar Insulin Revenue by Company (2020-2025)
3.2.2 Global Biosimilar Insulin Revenue Market Share by Company (2020-2025)
3.3 Global Biosimilar Insulin Sale Price by Company
3.4 Key Manufacturers Biosimilar Insulin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biosimilar Insulin Product Location Distribution
3.4.2 Players Biosimilar Insulin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Biosimilar Insulin by Geographic Region
4.1 World Historic Biosimilar Insulin Market Size by Geographic Region (2020-2025)
4.1.1 Global Biosimilar Insulin Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Biosimilar Insulin Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Biosimilar Insulin Market Size by Country/Region (2020-2025)
4.2.1 Global Biosimilar Insulin Annual Sales by Country/Region (2020-2025)
4.2.2 Global Biosimilar Insulin Annual Revenue by Country/Region (2020-2025)
4.3 Americas Biosimilar Insulin Sales Growth
4.4 APAC Biosimilar Insulin Sales Growth
4.5 Europe Biosimilar Insulin Sales Growth
4.6 Middle East & Africa Biosimilar Insulin Sales Growth
5 Americas
5.1 Americas Biosimilar Insulin Sales by Country
5.1.1 Americas Biosimilar Insulin Sales by Country (2020-2025)
5.1.2 Americas Biosimilar Insulin Revenue by Country (2020-2025)
5.2 Americas Biosimilar Insulin Sales by Type (2020-2025)
5.3 Americas Biosimilar Insulin Sales by Distribution Channel (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biosimilar Insulin Sales by Region
6.1.1 APAC Biosimilar Insulin Sales by Region (2020-2025)
6.1.2 APAC Biosimilar Insulin Revenue by Region (2020-2025)
6.2 APAC Biosimilar Insulin Sales by Type (2020-2025)
6.3 APAC Biosimilar Insulin Sales by Distribution Channel (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Biosimilar Insulin by Country
7.1.1 Europe Biosimilar Insulin Sales by Country (2020-2025)
7.1.2 Europe Biosimilar Insulin Revenue by Country (2020-2025)
7.2 Europe Biosimilar Insulin Sales by Type (2020-2025)
7.3 Europe Biosimilar Insulin Sales by Distribution Channel (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biosimilar Insulin by Country
8.1.1 Middle East & Africa Biosimilar Insulin Sales by Country (2020-2025)
8.1.2 Middle East & Africa Biosimilar Insulin Revenue by Country (2020-2025)
8.2 Middle East & Africa Biosimilar Insulin Sales by Type (2020-2025)
8.3 Middle East & Africa Biosimilar Insulin Sales by Distribution Channel (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biosimilar Insulin
10.3 Manufacturing Process Analysis of Biosimilar Insulin
10.4 Industry Chain Structure of Biosimilar Insulin
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biosimilar Insulin Distributors
11.3 Biosimilar Insulin Customer
12 World Forecast Review for Biosimilar Insulin by Geographic Region
12.1 Global Biosimilar Insulin Market Size Forecast by Region
12.1.1 Global Biosimilar Insulin Forecast by Region (2026-2031)
12.1.2 Global Biosimilar Insulin Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Biosimilar Insulin Forecast by Type (2026-2031)
12.7 Global Biosimilar Insulin Forecast by Distribution Channel (2026-2031)
13 Key Players Analysis
13.1 Eli Lilly
13.1.1 Eli Lilly Company Information
13.1.2 Eli Lilly Biosimilar Insulin Product Portfolios and Specifications
13.1.3 Eli Lilly Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Eli Lilly Main Business Overview
13.1.5 Eli Lilly Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Biosimilar Insulin Product Portfolios and Specifications
13.2.3 Sanofi Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Gan&Lee
13.3.1 Gan&Lee Company Information
13.3.2 Gan&Lee Biosimilar Insulin Product Portfolios and Specifications
13.3.3 Gan&Lee Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Gan&Lee Main Business Overview
13.3.5 Gan&Lee Latest Developments
13.4 Tonghua Dongbao
13.4.1 Tonghua Dongbao Company Information
13.4.2 Tonghua Dongbao Biosimilar Insulin Product Portfolios and Specifications
13.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Tonghua Dongbao Main Business Overview
13.4.5 Tonghua Dongbao Latest Developments
13.5 United Laboratory
13.5.1 United Laboratory Company Information
13.5.2 United Laboratory Biosimilar Insulin Product Portfolios and Specifications
13.5.3 United Laboratory Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 United Laboratory Main Business Overview
13.5.5 United Laboratory Latest Developments
13.6 Geropharm
13.6.1 Geropharm Company Information
13.6.2 Geropharm Biosimilar Insulin Product Portfolios and Specifications
13.6.3 Geropharm Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Geropharm Main Business Overview
13.6.5 Geropharm Latest Developments
13.7 Biocon
13.7.1 Biocon Company Information
13.7.2 Biocon Biosimilar Insulin Product Portfolios and Specifications
13.7.3 Biocon Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Biocon Main Business Overview
13.7.5 Biocon Latest Developments
13.8 Wockhardt
13.8.1 Wockhardt Company Information
13.8.2 Wockhardt Biosimilar Insulin Product Portfolios and Specifications
13.8.3 Wockhardt Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Wockhardt Main Business Overview
13.8.5 Wockhardt Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂